Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Mark Dynamics Indonesia Tbk (MARK.JK)
Deli Serdang, ID
PT Mark Dynamics Indonesia Tbk, headquartered in Deli Serdang, Indonesia, is dedicated to the manufacturing and distribution of porcelain molds. Their extensive product line includes formers tailored for various purposes, such as medical examinations, surgical procedures, household applications, custom specifications, and industrial uses. Furthermore, the company produces sanitary fittings like toilets, lavatories, and bathtubs, along with other ceramic articles including yellow and white molds, tableware, and raw porcelain clays. Founded in 2002, PT Mark Dynamics Indonesia Tbk also participates in the export market and operates as a subsidiary of Tecable (HK) Co. Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.05% | -1.85% | -2.45% | -1.24% | -5.92% | -3.05% | +3.92% | +32.50% | -16.32% | +962.83% | +962.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-8.0% Q1'26: +23.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-0.9% Q1'26: +19.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+33.2% Q1'26: +44.8% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+41.8% ★ Q1'26: +42.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+31.2% ★ Q1'26: +39.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: -99.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.17× Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.19T
est: 1.23T (-2.7%)
|
823.66B
est: 1.23T (-32.8%)
|
559.47B
est: 1.56T (-64.1%)
|
909.99B
est: 932.00B (-2.4%)
|
837.31B
est: 1.05T (-20.5%)
|
1.20T
1.20T – 1.20T
+14.0% YoY
|
1.32T
1.28T – 1.37T
+10.0% YoY
|
| EBITDA |
533.61B
est: 514.10B (+3.8%)
|
344.17B
est: 514.10B (-33.1%)
|
234.36B
est: 652.90B (-64.1%)
|
399.83B
est: 406.02B (-1.5%)
|
380.97B
est: 459.08B (-17.0%)
|
523.34B
523.34B – 523.34B
+14.0% YoY
|
575.66B
555.97B – 595.35B
+10.0% YoY
|
| EBIT |
512.43B
est: 473.72B (+8.2%)
|
321.66B
est: 473.72B (-32.1%)
|
204.05B
est: 601.62B (-66.1%)
|
368.77B
est: 374.61B (-1.6%)
|
350.31B
est: 423.57B (-17.3%)
|
482.86B
482.86B – 482.86B
+14.0% YoY
|
531.13B
512.96B – 549.30B
+10.0% YoY
|
| Net Income |
392.15B
est: 374.68B (+4.7%)
|
243.09B
est: 374.68B (-35.1%)
|
156.02B
est: 450.30B (-65.4%)
|
286.54B
est: 353.40B (-18.9%)
|
283.88B
est: 311.60B (-8.9%)
|
380.00B
380.00B – 380.00B
+22.0% YoY
|
418.00B
418.00B – 418.00B
+10.0% YoY
|
| SGA |
46.40B
est: 47.09B (-1.5%)
|
27.42B
est: 47.09B (-41.8%)
|
20.74B
est: 59.81B (-65.3%)
|
40.95B
est: 42.05B (-2.6%)
|
59.74B
est: 47.54B (+25.7%)
|
54.20B
54.20B – 54.20B
+14.0% YoY
|
59.61B
57.57B – 61.65B
+10.0% YoY
|
| EPS |
103.20
est: 98.60 (+4.7%)
|
63.97
est: 98.60 (-35.1%)
|
41.06
est: 118.50 (-65.4%)
|
75.40
est: 93.00 (-18.9%)
|
74.71
est: 82.00 (-8.9%)
|
100.00
100.00 – 100.00
+22.0% YoY
|
110.00
110.00 – 110.00
+10.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-26 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-25 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-22 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-21 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-20 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-19 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-18 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-13 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-08 | S | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-07 | S | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-06 | S | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 4/5 | 5/5 |
| 2026-05-05 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Budi Muharsyah | Head of Financial Department | — | — |
| Kun Jian Chow | Director & Senior Head of Marketing | — | male |
| Naomi Elisabeth Lumbantobing | Human Resource Manager | — | male |
| Riana | Director & Head of Internal Audit Unit | — | female |
| Ridwan Goh | CEO & President Director | — | male |
| Yuriani Trisjoyo | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MARK.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
